

Particulars	3 months ended 31.03.2018	3 months ended 31.12.2017	3 months ended 31.03.2017	Year ended 31.03.2018	Previous Year ended 31.03.2017
	(Audited) (Refer note 8)	(Unaudited)	(Audited) (Refer note 8)	(Audited)	(Audited)
Segment revenue					
a. Small molecules	4,255	3,688	3,948	15,077	16,405
b. Biologies	2,408	1,898	1,633	7,702	7,018
c. Branded formulations	1,491	1,561	1,310	6,115	5,489
d. Research services	4,091	3,877	2,828	14,231	11,925
Total	12,245	11,024	9,719	43,125	40,837
Less: Inter-segment revenue	(550)	(445)	(408)	(1,828)	(1,621)
Net sales/ Income from continuing operations	11,695	10,579	9,311	41,297	39,216
Segment results					
Profit before interest and tax from each segment					
a. Small molecules	852	820	1,066	2,843	4,142
b. Biologies <i>U</i>	194	(48)	59	(119)	1,397
c. Branded formulations #	123	79	99	428	463
d. Research services	1,044	977	902	3,725	3,465
Total	2,213	1,828	2,126	6,877	9,467
Less: Interest	98	94	22	388	86
Other un-allocable expenditure / (income), net	181	237	517	389	884
Profit before tax and before exceptional items #	1,934	1,497	1,587	6,100	8,497
Segment assets					
a. Small molecules	17,681	17,759	16,116	17,681	16,116
b. Biologies	36,038	34,434	34,111	36,038	34,111
c. Branded formulations	2,927	3,039	2,386	2,927	2,386
d. Research services	31,890	28,588	27,738	31,890	27,738
	88,536	83,820	80,351	88,536	80,351
e. Unallocable	11,361	12,447	13,591	11,361	13,591
Total segment assets	99,897	96,267	93,942	99,897	93,942
Segment liabilities					
a. Small molecules	4,320	4,722	3,548	4,320	3,548
b. Biologies	7,704	7,037	8,251	7,704	8,251
c. Branded formulations	1,872	2,135	1,650	1,872	1,650
d. Research services	14,686	11,899	13,607	14,686	13,607
	28,582	25,793	27,056	28,582	27,056
e. Unallocable	14,830	15,325	14,748	14,830	14,748
Total segment liabilities	43,412	41,118	41,804	43,412	41,804
Capital employed					
a. Small molecules	13,361	13,037	12,568	13,361	12,568
b. Biologies	28,334	27,397	25,860	28,334	25,860
c. Branded formulations	1,055	904	736	1,055	736
d. Research services	17,204	16,689	14,131	17,204	14,131
	59,954	58,027	53,295	59,954	53,295
e. Unallocable	(3,469)	(2,878)	(1,157)	(3,469)	(1,157)

Total capital employed	56,485	55,149	52,138	56,485	52,138
# includes share of profit/loss of joint venture and associates					